The Adult Cystic Fibrosis Team at University Hospital Galway is using online video conferencing to replace face-to-face outpatient appointments during the COVID-19 outbreak.
Patients at Galway University Hospitals have taken part in a landmark trial that demonstrates a significant advance in cystic fibrosis (CF) care. A new triple combination drug from Vertex pharmaceuticals, tezacaftor and ivacaftor -plus an experimental one, known as VX-659 - was tested on adult CF patients with the more common delta 508 gene mutation. Up to 90% of Irish CF patients have at least one copy of this mutation which causes CF.
